Praxis pauses one of its seizure programs after phase 2 fail

Praxis Precision Medicines’ epilepsy pipeline has suffered a setback after a next-gen NaV blocker failed to sufficiently reduce seizures in a phase 2/3 study. Praxis Precision Medicines’ epilepsy pipeline has suffered a setback after a next-gen NaV blocker failed to sufficiently reduce seizures in a phase 2/3 study. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events…

Source: FierceBiotech